Evaluating the use of meropenem in hematologic patients with febrile neutropenia

ConclusionsOur results support the safe reduction of the use of meropenem by changing the empiric treatment protocol for patients with hematologic malignancy and febrile neutropenia. As this study showed a lower resistance frequency to piperacillin/tazobactam than to ceftazidime, this antibiotic is the recommended alternative.

Source: Mediterranean Journal of Hematology and Infectious Diseases - October 30, 2023 Category: Hematology Authors: R.A. Stuurman, E. Jong, P.C.R. Godschalk, M.F. Corsten, J.E. Nagtegaal Source Type: research